CLINICAL TRIALS PROFILE FOR IMODIUM MULTI-SYMPTOM RELIEF
✉ Email this page to a colleague
All Clinical Trials for IMODIUM MULTI-SYMPTOM RELIEF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00075868 ↗ | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2003-12-01 | RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. |
| NCT00075868 ↗ | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer | Completed | Radiation Therapy Oncology Group | Phase 3 | 2003-12-01 | RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | Bausch Health Americas, Inc. | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | The University of Texas Health Science Center, Houston | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00360828 ↗ | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | Terminated | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2006-02-01 | Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects. |
| NCT00583531 ↗ | Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis | Terminated | Ocera Therapeutics | Phase 2 | 2007-03-01 | This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry. They may continue other previously prescribed treatments (e.g., probiotics and/or nutritional agents) at the discretion of the study doctor. The purpose of the study is to assess whether the investigational medication AST-120 will be a safe and effective treatment for the symptoms of pouchitis, a chronic inflammatory condition, in patients whose symptoms have not responded well to antibiotics. An initial group of 10 patients will be enrolled. If there are no serious side effects associated with the study drug and at least 3 of the 10 patients respond, a second group of 10 patients may be enrolled. Patients will have clinic visits at the start of the study and at week 4. Patients will be checked by phone on a weekly basis for symptom response, compliance and development of side effects. Endoscopies will be performed at the start of the study and at week 4 or early termination. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IMODIUM MULTI-SYMPTOM RELIEF
Condition Name
Clinical Trial Locations for IMODIUM MULTI-SYMPTOM RELIEF
Trials by Country
Clinical Trial Progress for IMODIUM MULTI-SYMPTOM RELIEF
Clinical Trial Phase
Clinical Trial Sponsors for IMODIUM MULTI-SYMPTOM RELIEF
Sponsor Name
